Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Advertisement
Scientific Reports volume 13, Article number: 250 (2023)
Metrics details
Type 2 diabetes mellitus (T2DM) and diminished myocardial perfusion increase the risk of heart failure (HF) and/or all-cause mortality during 6-year follow up following primary percutaneous coronary intervention (pPCI) for ST elevation myocardial infarction (STEMI). The aim of the present study was to evaluate the impact of myocardial perfusion on infarct size and left ventricular ejection fraction (LVEF) in patients with T2DM and STEMI treated with pPCI. This is an ancillary analysis of an observational cohort study of T2DM patients with STEMI. We enrolled 406 patients with STEMI, including 104 with T2DM. Myocardial perfusion was assessed with the Quantitative Myocardial Blush Evaluator (QUBE) and infarct size with the creatine kinase myocardial band (CK-MB) maximal activity and troponin area under the curve. LVEF was measured with biplane echocardiography using Simpson’s method at admission and hospital discharge. Analysis of covariance was used for modeling the association between myocardial perfusion, infarct size and left ventricular systolic function. Patients with T2DM and diminished perfusion (QUBE below median) had the highest CK-MB maximal activity (252.7 ± 307.2 IU/L, P < 0.01) along with the lowest LVEF (40.6 ± 10.0, P < 0.001). Older age (p = 0.001), QuBE below median (p = 0.026), and maximal CK-MB activity (p < 0.001) were independent predictors of LVEF. Diminished myocardial perfusion assessed by QuBE predicts significantly larger enzymatic infarct size and lower LVEF among patients with STEMI treated with pPCI, regardless of diabetes status.
Diabetes mellitus remains an important risk factor for worse prognosis in patients after acute ST-segment-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI)1,2,3,4. Although pPCI is the optimal choice of reperfusion therapy in such conditions5,6, even timely performed procedures resulting in recanalization of the culprit vessel may still yield disappointing results. This phenomenon is thought to be related to impaired myocardial perfusion7,8,9,10.
Type 2 diabetes mellitus (T2DM) is associated with diminished myocardial perfusion after reperfusion11,12,13, and even otherwise healthy patients with T2DM exhibit myocardial perfusion defects14. Therefore, it is important to establish how this pathology translates into patient clinical outcomes.
We have previously reported that T2DM and diminished myocardial perfusion increased the clinical risks of heart failure (HF) and/or all-cause mortality during 6-year follow-up following pPCI for STEMI15. In our study it was also noted that patients with diabetes had worse myocardial perfusion or epicardial flow presented with larger enzymatic infarct size and lower left ventricular ejection fraction (LVEF) when compared to patients without T2DM15. Indeed, LVEF is a potent and most commonly used functional marker of the severity of the underlying myocardial injury16, yet another robust predictor of adverse events following STEMI is infarct size17.
The aim of the study was to evaluate the impact of myocardial perfusion on infarct size and LVEF in patients with T2DM and STEMI treated with pPCI. We tested the hypothesis that patients with T2DM and STEMI treated with pPCI with diminished myocardial perfusion, would have significantly larger enzymatic infarct size and lower LVEF.
This is an ancillary analysis of a single center, retrospective, cohort study of patients treated with pPCI due to STEMI. The main results for the clinical outcomes have been published15. In brief, we have reviewed 1469 consecutive STEMI patients, who were admitted to cardiology ward from January 2004 until December 2014, out of them 406 patients have fulfilled the following inclusion criteria: age ≥ 18 years old, complete hospital medical records, good quality electrocardiographic tracings and angiograms, and the absence of HF before the hospital admission. Exclusion criteria comprised of coronary artery lesions not amenable to stent implantation or balloon angioplasty, chronic total coronary occlusion which could not be revascularized or referral of the patient for bypass surgery.
Every patient signed a suitable informed consent for in-hospital treatment on admission and no additional consent related to this analysis was necessary since only anonymized registry data has been analyzed. The study protocol has been approved by the Medical University of Silesia Ethics Committee (No. PCN/0022/KB/92/20) and the need for informed consent was waived by this Ethics Committee. All methods were performed in accordance with relevant regulations and the study was conducted in accordance with the Declaration of Helsinki.
Myocardial perfusion has been measured in patients’ angiograms with QuBE value using an on-line software available at http://qube.sourceforge.net/. The code for QuBE software is publicly available at https://github.com/mathijs81/qube and has been developed by the University Medical Center Groningen, the Netherlands and thoroughly described by Vogelzang et al.18. In brief, the method involves operator-independent, digital analysis of angiogram and calculation of myocardial perfusion score (the higher score reflects better myocardial perfusion). In order to check intra- and inter-rater reliability, random sample of angiograms were analyzed twice by each of the two observers. The inter- and intra-patient variability of QuBE values was 94.5% and 99.7%, respectively. This analysis was performed on 34 angiograms19.
Infarct size was assessed by peak activity of creatine kinase myocardial band isoenzyme (CK-MB) and troponin T concentration area under the curve (AUC), measured on hospital admission and 12, 24 and 72 h following admission. Echocardiographic measurement of LVEF was performed on the day of admission and hospital discharge. Detailed information from angiographic reanalysis, angiographic assessment of myocardial perfusion, assessment of infarct size, echocardiographic measurements as well as overview of methods used to obtain biochemical data have been reported previously19.
Descriptive statistics were calculated for all the variables, including continuous variables (reported as mean values and standard deviations) and categorical variables (reported as numbers and percentages). The QuBE variable as a binary one was used to stratify patients into groups 1 to 4, according to its median value, then as a continuous variable was used for further analyses. Comparisons were performed using t tests, χ2 tests with Yates correction. The one-way or Kruskal ANOVA were used for multiple groups comparisons. Any significance detected with ANOVA was reassessed with χ2 or t test with Bonferroni correction for categorical or continuous variables where appropriate. Analysis of covariance was used to adjust for confounding variables. We considered variable as a confounding one if differ significantly among the groups 1 to 4 presented in Tables 1 and 2. All the statistical analyses were performed using Statistica 13 (Statsoft Inc., Tulsa, Oklahoma, USA), and p values < 0.05 were considered to be statistically significant.
The study protocol has been approved by the Medical University of Silesia Ethics Committee (No. PCN/0022/KB/92/20).
Baseline characteristics of the 406 patients (mean age 62.1 ± 10.9 years, 32.8% female) according to QuBE values and presence of T2DM are shown in Table 1. The study population was divided into four groups based on the median QuBE value (9 arbitrary units) and T2DM diagnosis. Differences in age and sex between the groups were significant (p < 0.001, p < 0.01, respectively) whereby patients with T2DM and diminished perfusion were significantly older (p < 0.001), and had the lowest eGFR (p < 0.001). Frequency of previous MI (myocardial infarction) and location of current MI (anterior or inferior) did not differ between groups.
Subjects with T2DM and diminished myocardial perfusion had the highest peak CK-MB levels and worst mean LVEF, despite similar troponin T AUC and cTFC (corrected TIMI frame count) levels (Table 2).
Considering the subgroup of patients with T2DM, those with QuBE score below median had worse procedural outcomes in comparison to patients with higher QuBE score: LVEF was lower (p = 0.017), and peak CK-MB was greater (p = 0.02), but there were no significant differences in troponin T AUC and epicardial flow in infarct-related artery (number of cTFC). There were significantly fewer patients with hypertension and smokers (Table 1). The duration of diabetes was 6.4 ± 4.1 years, all patients were treated with oral hypoglycemic drugs, and 12 patients were treated with insulin. T2DM patients from group 3 and group 4 did not differ in relation to diabetes duration, nor the type of diabetes treatment.
In analysis of covariance, older age (p = 0.001), QuBE below median (p = 0.026), and maximal CK-MB activity (p < 0.001) were independent predictors of LVEF (Table 3).
The interrelationship between QuBE, peak CK-MB, and LVEF in patients with T2DM is depicted in Fig. 1. The lowest mean LVEF values are seen in patients with the lowest QuBE and highest maximal CK-MB activity. Similar trends can be seen in patients without T2DM in Fig. 2.
Graphical presentation of the relationship between peak CK-MB activity and QuBE (A) as well as LVEF and QuBE (B) in T2DM patients.
Graphical presentation of the relationship between peak CK-MB activity and QuBE (A) as well as LVEF and QuBE (B) in nondiabetic patients.
In this ancillary analysis of an observational cohort study of T2DM patients with STEMI undergoing pPCI, we found that diminished left ventricular perfusion as quantified by QuBE was associated with significantly larger enzymatic infarct size and lower LVEF in both patients with T2DM and these without it, regardless of factors such as epicardial blood flow (measured by cTFC) or MI location. Second, older patients with T2DM had worse myocardial perfusion, greater peak CK-MB activity, and lower LVEF. These observations provide supplementary evidence to support our prior clinical observations that T2DM and diminished myocardial perfusion increase the risk of HF and/or all-cause mortality during 6-year follow up15.
In this study, QuBE correlated with LVEF, a well-established marker for prognosis of outcomes of patients after pPCI consistent with our previous finding that diminished myocardial perfusion assessed by QuBE was lower in patients with T2DM and was associated with higher long-term risk of HF and/or all-cause mortality. Therefore, QUBE could potentially be useful in risk assessment of patients with T2DM after pPCI due to STEMI.
Associations between infarct size, LV function and myocardial perfusion have been previously studied in patients with acute MI treated with pPCI using a wide variety of diagnostic modalities. Studies based on cardiac magnetic resonance (CMR) measurements showed that infarct size correlates with LVEF and subjects with microvascular obstruction had larger infarct size17. Similarly, infarct size as assessed by Single Photon Emission Computed Tomography (SPECT) closely correlates with LVEF20. Recently published study by Assante et al.21 provides the evidence for increased cardiovascular risk in diabetic patients with impaired myocardial perfusion assessed with positron emission tomography.
Limited data exist regarding enzymatic method estimating infarct size and measures of myocardial perfusion based on angiography. Consistent with the current study, Henriques et al.22 demonstrated that patients with worse myocardial perfusion had larger enzymatic infarct size and lower LVEF; however, Henriques et al. graded myocardial perfusion as a categorical variable using Myocardial Blush Grade (MBG), hence no detailed relationship between myocardial perfusion and infarct size was described. Also, infarct size estimated by release of CK-MB was larger when myocardial perfusion measured by MBG was worse, although again, conducted analysis considered perfusion as a categorical variable23.
There are other methods such as contrast echocardiography18 or magnetic resonance imaging24 used to evaluate myocardial perfusion, albeit not routinely, because of cost, limited access and equipment required. In contrast, QuBE can be assessed immediately after pPCI procedure with little effort. Another advantage of QuBE is the limited inter- and intra-observer variability18,19 as well as its continuous data output, in contrast to MBG and TIMI Myocardial Perfusion Grade (TMPG) which are graded visually as discrete values.
Few studies have addressed whether microvascular obstruction of myocardium is more extensive in patients with diabetes and STEMI and how it impacts their clinical outcomes. Two studies11,13 showed that patients with T2DM are more likely to have reduced myocardial perfusion, but others have presented opposing results25. Notably, these trials utilized different methods for myocardial perfusion assessment, that is, MBG and STR (ST segment resolution) in the studies that showed significant associations11,13 or the use of TMPG in study that did not25. Of note, there was no correlation between angiographic MBG and method based on contrast echocardiography TMPG for myocardial perfusion assessment26. In the current study, the patients with T2DM had lower myocardial perfusion measured by QuBE.
Although patients with T2DM had numerically lower CK-MB activities, those with poor myocardial perfusion (QuBE below median) had the greatest CK-MB activities in the study. Prior reports evaluating whether a relationship between diabetes and CK exists in a population of patients with acute MI had opposing results. For example, post-hoc analyses of the SAVE and CORE trials demonstrated significantly lower peak CK (all isozymes) when diabetes was present27,28. A case control study reported increased peak CK and CK-MB in patients with diabetes29. This discrepancy may be explained partly by differing baseline characteristics of patients between studies and poor characterization of study population in the observational study, whereby many potential confounders were not controlled for.
Another challenge is to establish whether worse outcomes associated with diabetes result from more extensive myocardial injury as compared to nondiabetics. Several studies11,28,30,31,32,33,34,35 analyzed infarct size, LVEF and other myocardial damage markers obtained by means of different imaging modalities (CMR, SPECT, echocardiography, or angiography). Although most studies reported the lack of diabetes impact on infarct size and LVEF30,31,32,33,34,35, there are also studies with conflicting results. For example, Marso et al.11 found significantly larger infarct size in patients with diabetes, possibly caused by worse myocardial perfusion in this group. A post-hoc analysis of the VALIANT trial34 did not reveal differences in regard to LVEF between patients with and without diabetes; however, an analysis of patient subgroups stratified by LVEF and diabetes in this study showed a reduced risk of adverse events (death or HF hospitalizations) with increasing LVEF although the magnitude of this risk reduction was smaller among patients with diabetes. A sub-study of the CORE trial showed that patients with diabetes and STEMI had larger infarct size and lower LVEF, but this alone cannot fully explain the much higher mortality of patients with diabetes28. Interestingly, Zia et al. showed increased myocardial oedema32, advocating another possible mechanism causing worse outcomes in diabetic STEMI patients.
While the aforementioned studies utilized different treatment regimens and modalities for assessment of functional parameters, the associations between parameters of myocardial perfusion, infarct size, left systolic function and DM were nonexistent or modest, but worse long-term clinical outcomes (MACE (major adverse cardiovascular events) or mortality) for patients with diabetes were consistent across all studies, ranging from approximately 40% to eightfold increased risk11,28,30,31,33,34,35.
The present study has several limitations. These include a relatively small sample size, and recruitment from one center in a retrospective manner. It has to be noted, that assessment of microvascular perfusion based on angiography is much less precise compared to other modalities, such as CMR. Consequently, it has been shown that microvascular obstruction seen in CMR is better at predicting outcomes than MBG36. Moreover, one must bear in mind that a non-standard method of QuBE measurement has been applied in this analysis. Additionally, since the time of patient recruitment, changes have emerged in the therapy of diabetic STEMI patients, including new hypoglycemic agents such as sodium-glucose co-transporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists, which have cardioprotective effects. For example, liraglutide and canagliflozin administration significantly reduce infarct size in animal models37,38 and exenatide reduces infarct size in patients treated with pPCI due to STEMI39. Furthermore, advancements in pPCI are evident, including drug-eluting stents, reduced use of adjunctive thrombectomy and the introduction of new antiplatelet drugs.
Diminished myocardial perfusion assessed by QuBE predicts significantly larger enzymatic infarct size and lower LVEF among patients with STEMI treated with pPCI, regardless of diabetes status.
The datasets used and analysed during the current study are available from the corresponding author on reasonable request.
Type 2 diabetes mellitus
Heart failure
Primary percutaneous coronary intervention
ST elevation myocardial infarction
Left ventricular ejection fraction
Quantitative Myocardial Blush Evaluator
Creatine kinase
Creatine kinase myocardial band
Area under the curve
Corrected TIMI frame count
Myocardial infarction
Left ventricle
Cardiac magnetic resonance
Single photon emission computed tomography
Myocardial blush grade
TIMI myocardial perfusion grade
ST segment resolution
Major adverse cardiovascular events
Reindl, M. et al. ACEF score adapted to ST-elevation myocardial infarction patients: The ACEF-STEMI score. Int. J. Cardiol. 264, 18–24 (2018).
Article Google Scholar
Brener, S. J. et al. Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study. Eur. Heart J. 29(9), 1127–1135 (2008).
Article Google Scholar
De Luca, G. et al. Impact of diabetes on long-term outcome after primary angioplasty. Diabetes Care 36(4), 1020–1025 (2013).
Article Google Scholar
Timmer, J. R. et al. Long-term, cause-specific mortality after myocardial infarction in diabetes. Eur. Heart J. 25(11), 926–931 (2004).
Article Google Scholar
Ibanez, B. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 39(2), 119–177 (2018).
Article Google Scholar
Timmer, J. R. et al. Primary percutaneous coronary intervention compared with fibrinolysis for myocardial infarction in diabetes mellitus: Results from the primary coronary angioplasty vs thrombolysis-2 trial. Arch. Intern. Med. 167(13), 1353–1359 (2007).
Article Google Scholar
Gibson, C. M. et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 101(2), 125–130 (2000).
Article CAS Google Scholar
van’t Hof, A. W. et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade: Zwolle Myocardial Infarction Study Group. Circulation 97(23), 2302–2306 (1998).
Article Google Scholar
Hiroshi, I. et al. Clinical implications of the ‘no reflow’ phenomenon. Circulation 93(2), 223–228 (1996).
Article Google Scholar
Niccoli, G., Scalone, G., Lerman, A. & Crea, F. Coronary microvascular obstruction in acute myocardial infarction. Eur. Heart J. 37(13), 1024–1033 (2016).
Article Google Scholar
Marso, S. P. et al. Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD trial). Am. J. Cardiol. 100(2), 206–210 (2007).
Article Google Scholar
De Luca, G. et al. Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb–IIIa inhibitors. Atherosclerosis 207(1), 181–185 (2009).
Article Google Scholar
Prasad, A. et al. Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 45(4), 508–514 (2005).
Article Google Scholar
Roldano, S., Christian, N., Vigili, D. K. S., Antonio, T. & Angelo, A. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation 112(2), 179–184 (2005).
Article Google Scholar
Tomasik, A. et al. Effect of diabetes mellitus and left ventricular perfusion on frequency of development of heart failure and/or all-cause mortality late after acute myocardial infarction. Am. J. Cardiol. 10, 25–32 (2020).
Google Scholar
Burns, R. J. et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J. Am. Coll. Cardiol. 39(1), 30–36 (2002).
Article Google Scholar
Wu, E. et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: Prospective cohort study. Heart 94(6), 730–736 (2008).
Article CAS Google Scholar
Vogelzang, M. et al. Computer-assisted myocardial blush quantification after percutaneous coronary angioplasty for acute myocardial infarction: A substudy from the TAPAS trial. Eur. Heart J. 30(5), 594–599 (2009).
Article Google Scholar
Tomasik, A. et al. Quantitative myocardial blush score (QuBE) allows the prediction of heart failure development in long-term follow-up in patients with ST-segment elevation myocardial infarction: Proof of concept study. Cardiol. J. 26(4), 322–332 (2019).
Article Google Scholar
Sciagrà, R. et al. Relationship of infarct size and severity versus left ventricular ejection fraction and volumes obtained from 99mTc-sestamibi gated single-photon emission computed tomography in patients treated with primary percutaneous coronary intervention. Eur. J. Nucl. Med. Mol. Imaging. 31(7), 969–974 (2004).
Article Google Scholar
Assante, R. et al. Relation between myocardial blood flow and cardiac events in diabetic patients with suspected coronary artery disease and normal myocardial perfusion imaging. J. Nucl. Cardiol. 28(4), 1222–1233 (2021).
Article Google Scholar
Henriques, J. P. S. et al. Angiographic assessment of reperfusion in acute myocardial infarction by Myocardial Blush Grade. Circulation 107(16), 2115–2119 (2003).
Article Google Scholar
De Luca, G. et al. Combination of electrocardiographic and angiographic markers of reperfusion in the prediction of infarct size in patients with ST-segment elevation myocardial infarction undergoing successful primary angioplasty. Int. J. Cardiol. 117(2), 232–237 (2007).
Article Google Scholar
Porto, I. et al. Quantitative Blush Evaluator accurately quantifies microvascular dysfunction in patients with ST-elevation myocardial infarction: Comparison with cardiovascular magnetic resonance. Am. Heart J. 162(2), 372-381.e2 (2011).
Article Google Scholar
Brener, S. J., Mehran, R., Dressler, O., Cristea, E. & Stone, G. W. Diabetes mellitus, myocardial reperfusion, and outcome in patients with acute ST-elevation myocardial infarction treated with primary angioplasty (from HORIZONS AMI). Am. J. Cardiol. 109(8), 1111–1116 (2012).
Article Google Scholar
Rasoul, S., Dambrink, J. H. E., Breeman, A., Elvan, A. & van’t Hof, A. W. J. The relation between myocardial blush grade and myocardial contrast echocardiography: which one is a better predictor of myocardial damage?. Neth Heart J. 18(1), 25–30 (2010).
CAS Google Scholar
Murcia, A. M. et al. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch. Intern. Med. 164(20), 2273–2279 (2004).
Article Google Scholar
Alegria, J. R., Miller, T. D., Gibbons, R. J., Yi, Q. L. & Yusuf, S. Infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapy. Am. Heart J. 154(4), 743–750 (2007).
Article Google Scholar
Ali, F., Naqvi, S. A. S., Bismillah, M. & Wajid, N. Comparative analysis of biochemical parameters in diabetic and non-diabetic acute myocardial infarction patients. Indian Heart J. 68(3), 325–331 (2016).
Article Google Scholar
Reinstadler, S. J. et al. Relationship between diabetes and ischaemic injury among patients with revascularized ST-elevation myocardial infarction. Diabetes Obes. Metab. 19(12), 1706–1713 (2017).
Article CAS Google Scholar
Sanidas, E. A. et al. Outcomes in diabetic patients undergoing primary percutaneous coronary intervention for acute anterior myocardial infarction: Results from the INFUSE-AMI study. Catheter. Cardiovasc. Interv. 83(5), 704–710 (2014).
Article Google Scholar
Zia, M. I. et al. Comparison of the frequencies of myocardial edema determined by cardiac magnetic resonance in diabetic versus nondiabetic patients having percutaneous coronary intervention for ST elevation myocardial infarction. Am. J. Cardiol. 113(4), 607–612 (2014).
Article Google Scholar
Eitel, I. et al. Prognostic impact of hyperglycemia in nondiabetic and diabetic patients with ST-elevation myocardial infarction. Circ. Cardiovasc. Imaging. 5(6), 708–718 (2012).
Article Google Scholar
Shah, A. M. et al. The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. Eur. J. Heart Fail. 12(11), 1229–1237 (2010).
Article CAS Google Scholar
Shah, A. M. et al. Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren. Eur. J. Heart Fail. 14(2), 185–192 (2012).
Article CAS Google Scholar
Nijveldt, R. et al. Functional recovery after acute myocardial infarction. J. Am. Coll. Cardiol. 52(3), 181–189 (2008).
Article Google Scholar
Noyan-Ashraf, M. H. et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58(4), 975–983 (2009).
Article CAS Google Scholar
LimVen, G. et al. SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart. JACC Basic Transl. Sci. 4(1), 15–26 (2019).
Article CAS Google Scholar
Lønborg, J. et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur. Heart J. 33(12), 1491–1499 (2012).
Article Google Scholar
Download references
The study was supported by Medical University of Silesia grant No PCN-1-211/K/1/K.
These authors contributed equally: Katarzyna Nabrdalik and Andrzej Tomasik.
Department of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
Katarzyna Nabrdalik, Hanna Kwiendacz & Janusz Gumprecht
Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK
Katarzyna Nabrdalik & Gregory Y. H. Lip
Students’ Scientific Association By the Department of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
Krzysztof Irlik & Mirela Hendel
2nd Department of Cardiology in Zabrze, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
Andrzej Tomasik, Edyta Radzik, Katarzyna Pigoń, Tomasz Młyńczak & Ewa Nowalany-Kozielska
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
Gregory Y. H. Lip
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
K.N., A.T., J.G. and E.N.K. conceptualized study design; K.I., K.N., A.T. wrote original manuscript; K.N., A.T., M.H., J.G. and G.L. reviewed paper. T.M., E.R., K.P., K.N., H.K. and A.T. were involved in the data collection and T.M., E.R., K.P., K.N., M.H., H.K., A.T. and G.L. in data analysis. All authors edited and approved the final version of the manuscript. All the authors have read the manuscript and approved its contents.
Correspondence to Katarzyna Nabrdalik.
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Reprints and Permissions
Nabrdalik, K., Tomasik, A., Irlik, K. et al. Low Quantitative Blush Evaluator score predicts larger infarct size and reduced left ventricular systolic function in patients with STEMI regardless of diabetes status. Sci Rep 13, 250 (2023). https://doi.org/10.1038/s41598-022-24855-6
Download citation
Received: 17 April 2022
Accepted: 21 November 2022
Published: 05 January 2023
DOI: https://doi.org/10.1038/s41598-022-24855-6
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
Advertisement
© 2023 Springer Nature Limited
Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.